AGLE - Aeglea Bio regains Nasdaq compliance

• Clinical-stage biotech Aeglea BioTherapeutics ( NASDAQ: AGLE ) announced Tuesday that the company regained Nasdaq compliance related to the minimum closing price after its shares traded at $1.00 or higher over ten consecutive business days through Nov. 11.
• On July 18, Nasdaq notified that Aeglea ( AGLE ) was not in compliance with the exchange’s rules for continued listing as its shares had dropped below the minimum closing price of $1.00 for 30 days consecutively.
• The company had 180 calendar days, or until Jan. 16, to regain compliance, and it received Nasdaq’s notice of regaining compliance on Nov. 14.
• Aeglea ( AGLE ) shares added ~61% on Oct. 28 after Wells Fargo upgraded the stock to Overweight from Equal Weight, citing an upcoming data readout.

For further details see: